Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03502200 · ClinicalTrials.gov registry record · NA
Switching to a Vaping Device: Evaluating Risk Reduction Among Quitline Treatment Failures
A NA study, sponsored by Ohio State University Comprehensive Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 350
- Enrollment target
NCT03502200 is a NA study that has completed, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 350 participants.
The verdict
NCT03502200, a NA study, has completed, sponsored by Ohio State University Comprehensive Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 350 participants
- Enrollment target
Study Summary
The overall aim of the study is to evaluate the provision of e-cigarette (EC) versus NRT on smoking behavior, product use patterns and continued use, and iCO, a biomarker of toxicant exposure, among a sample of recent QL treatment failures. We will randomly assign N=372 smokers (targeted accrual) to EC (n=186) or QL treatment as usual with combination nicotine replacement therapy (NRT; n=186). All participants will receive three calls from QL coaches and EC and NRT will be provided at no cost for 8 weeks. The final follow-up will occur 12-weeks post baseline.
Interventions
- OTHER Treatment As Usual
- DEVICE JUUL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 350 participants |
| Start Date | 2020-10-15 |
| Est. Completion | 2023-01-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03502200
The ClinicalTrials.gov registry entry for NCT03502200 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 350 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ohio State University Comprehensive Cancer Center, which has 341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Treatment As Usual is the first listed.
NCT03502200 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03502200 about?
NCT03502200 is a clinical study titled "Switching to a Vaping Device: Evaluating Risk Reduction Among Quitline Treatment Failures". The overall aim of the study is to evaluate the provision of e-cigarette (EC) versus NRT on smoking behavior, product use patterns and continued use, and iCO, a biomarker of toxicant exposure, among a sample of recent QL treatment failures. We will randomly assign N=372 smokers (targeted accrual) to...
What is the current status of trial NCT03502200?
This trial is currently completed. It is a NA study. The enrollment target is 350 participants. The study started on 2020-10-15. Estimated completion is 2023-01-31.
What interventions are being tested in trial NCT03502200?
The interventions under investigation include: Treatment As Usual (OTHER), JUUL (DEVICE).
Who is sponsoring clinical trial NCT03502200?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.